352328-55-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Amino-2-methylsulfanyl-pyrimidin-5-yl)-ethanone is used as a potential pharmaceutical compound for its possible antiviral, antibacterial, and anticancer properties. Its unique structure with a pyrimidine ring and functional groups may contribute to its biological activity, making it a candidate for further research and development in the pharmaceutical field.
Further research and studies are needed to fully understand the properties and potential uses of 1-(4-Amino-2-methylsulfanyl-pyrimidin-5-yl)-ethanone, as its specific applications and efficacy are yet to be determined.

Upstream product

• 588-36-3 (4-amino-2-(methylthio)pyrimidin-5-yl)methanol 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 776-53-4 ethyl 4-amino-2-methylmercaptopyrimidine-5-carboxylate 
• 770-31-0 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde 
• 352328-54-2 1-(4-amino-2-methylsulfanylpyrimidin-5-yl)ethanol 

Downstream Products

• 850628-76-1 5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 352327-45-8 1[-6-Fluoro-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-isopropyl-urea 
• 850628-86-3 6-acetyl-8-cyclopentyl-5-methyl-2-(methylsulfinyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 571190-30-2 PD 0332991 

Relevant academic research and scientific papers

PYRIDOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, where X is O or S; R1 is hydrogen, an optionally substituted C1-6 alkyl, or an optionally substituted C3-8 cycloalkyl; each of R2/

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4

Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer. The pyrido[2,3-d]-pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples. Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging. Here, we report that the introduction of a methyl substituent at the C-5 position of the pyrido[2,3-d]pvrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases. Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro. The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.

Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

Disclosed are compounds of the formula (I) wherein: R2, R7, RI3, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH2)nR12; R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9; R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —Co2R9, —COR9, —CONR9R10, —NR9COR10, (un)substiuted lower alkenyl, or (un)substituted lower alkynyl; R8 is —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14, —PO(NR13R14)2; R9 and R10 are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.